Zimbabwe has turned down a significant American healthcare agreement worth 367 million US dollars (272 million pounds) over five years over Washington's demand for sensitive information.
This rejection became public after a official document dated December was disclosed, indicating that President Emmerson Mnangagwa felt the deal was "lopsided".
A government representative later clarified that the US was demanding access to health data for research and commercial purposes while refused to guarantee the benefits from any future vaccines.
"We must now begin the difficult and regrettable task of ending our health aid in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy indicated the US had provided more than $1.9bn in health funding to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has called for continued negotiations to find a agreement acceptable to all parties so the country's critical HIV treatment initiative can proceed.
Broader Background
This rejection comes after a comparable case in Kenya, where a court halted a related health funding agreement after concerns were filed about the security of citizens' health data.
After resuming office last year, US President Donald Trump has slashed foreign aid and closed the key foreign aid agency.
USAID had managed aid for the US government, but Trump claimed its spending was "inefficient" and his government was seeking government-to-government agreements to boost openness and accountability.
As per statements, Sixteen nations in Africa have so far signed these new health pacts, representing over $18.3bn in new funding.
Details of the Rejected Deal
This assistance for Zimbabwe would have supported "combating HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"It is our view this collaboration might have yielded immense advantages for the people of Zimbabwe, particularly the 1.2 million men, women and children presently on antiretroviral therapy through American-funded programmes," Tremont commented.
However, official spokesman Nick Mangwana maintained the proposed deal was "unequal".
"Zimbabwe was being asked to provide its biological resources and data indefinitely, with no corresponding assurance of benefiting from any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that might result from that provided information," he stated.
"Put simply, our country would provide the raw materials for medical research with no certainty that the final treatments would be available to our population if a new disease outbreak emerge."
National Interest and Global Health
Mangwana further noted that the US's withdrawal from the global health body and its push of one-on-one deals were undermining systems already set up through the global health agency.
Mangwana gave as an example its Pathogen Access and Benefit Sharing framework created to manage potential pandemics.
"This framework is intended to guarantee that when a nation contributes its information, the benefits – such as vaccines and treatments – are distributed fairly, not monopolised solely by those with the capability to develop them."
These objections regarding the US deal "must not be interpreted as opposition to America," Mangwana stressed.
"We are open to continued dialogue with our American counterparts on how subsequent co-operation could be structured in a way that honours the independence and interests of each country."
Health Experts Reaction
Medical experts expressed it understood the official position, but urged that talks should continue since much of the nation's Aids initiatives depended on external financing.
"If specific concerns arise, such as those relating to information security or implementation frameworks, these can frequently be resolved via technical clarification and mutually agreed protections," the group said.
This impasse emphasises the ongoing tensions between accepting much-needed foreign assistance and protecting local interests in an increasingly data-driven world.